MA49394A - Procédé de fabrication d'anticorps bispécifiques, anticorps bispécifiques et utilisation thérapeutique desdits anticorps - Google Patents
Procédé de fabrication d'anticorps bispécifiques, anticorps bispécifiques et utilisation thérapeutique desdits anticorpsInfo
- Publication number
- MA49394A MA49394A MA049394A MA49394A MA49394A MA 49394 A MA49394 A MA 49394A MA 049394 A MA049394 A MA 049394A MA 49394 A MA49394 A MA 49394A MA 49394 A MA49394 A MA 49394A
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- bispecific antibodies
- therapeutic use
- manufacturing
- bispecific
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762518090P | 2017-06-12 | 2017-06-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA49394A true MA49394A (fr) | 2020-04-22 |
Family
ID=62948274
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA049394A MA49394A (fr) | 2017-06-12 | 2018-06-08 | Procédé de fabrication d'anticorps bispécifiques, anticorps bispécifiques et utilisation thérapeutique desdits anticorps |
Country Status (25)
Country | Link |
---|---|
US (2) | US20190002589A1 (fr) |
EP (1) | EP3638692A1 (fr) |
JP (2) | JP7106234B2 (fr) |
KR (2) | KR20200005746A (fr) |
CN (1) | CN110730788A (fr) |
AR (1) | AR112419A1 (fr) |
AU (2) | AU2018284303B2 (fr) |
BR (1) | BR112019025904A2 (fr) |
CA (1) | CA3061097A1 (fr) |
CL (1) | CL2019003613A1 (fr) |
CO (1) | CO2019013838A2 (fr) |
CR (1) | CR20190558A (fr) |
CU (1) | CU20190100A7 (fr) |
EA (1) | EA201992670A1 (fr) |
EC (1) | ECSP19087580A (fr) |
IL (1) | IL271179A (fr) |
JO (1) | JOP20190283B1 (fr) |
MA (1) | MA49394A (fr) |
MX (1) | MX2019015021A (fr) |
PE (1) | PE20200384A1 (fr) |
SG (1) | SG10201913536TA (fr) |
TW (1) | TWI826377B (fr) |
UY (1) | UY37758A (fr) |
WO (1) | WO2018229612A1 (fr) |
ZA (1) | ZA201906757B (fr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
JOP20200308A1 (ar) * | 2012-09-07 | 2017-06-16 | Novartis Ag | جزيئات إرتباط il-18 |
EP3092049A1 (fr) | 2014-01-08 | 2016-11-16 | Flodesign Sonics Inc. | Dispositif d'acoustophorèse avec double chambre acoustophorétique |
CN110658340B (zh) * | 2015-01-08 | 2023-10-31 | 苏州康宁杰瑞生物科技有限公司 | 具有共同轻链的双特异性抗体或抗体混合物 |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
CN108283001B (zh) | 2015-10-08 | 2022-08-19 | 酵活有限公司 | 包含κ和λ轻链的抗原结合多肽构建体及其用途 |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
UY37758A (es) | 2017-06-12 | 2019-01-31 | Novartis Ag | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos |
KR20220066413A (ko) | 2017-12-14 | 2022-05-24 | 프로디자인 소닉스, 인크. | 음향 트랜스듀서 구동기 및 제어기 |
JP2021523894A (ja) * | 2018-05-09 | 2021-09-09 | ノバルティス アーゲー | カナキヌマブの使用 |
CN111018969A (zh) * | 2019-12-27 | 2020-04-17 | 上海药明生物技术有限公司 | 采用轻链select联合层析色谱纯化双特异性抗体的方法 |
CN115066258A (zh) * | 2020-02-28 | 2022-09-16 | 上海药明生物技术有限公司 | 双特异性抗体的纯化 |
US20220177569A1 (en) * | 2020-11-18 | 2022-06-09 | Novartis Ag | Bispecific Antibodies for use in treatment of NLRC4-GOF inflammasomapathy |
JP2023535884A (ja) | 2021-06-22 | 2023-08-22 | ノバルティス アーゲー | 化膿性汗腺炎の処置における使用のための二特異性抗体 |
CN113980135B (zh) * | 2021-12-27 | 2022-04-19 | 三优生物医药(上海)有限公司 | 一种结合冠状病毒双特异性抗体的抗药抗体及其制备方法和应用 |
WO2023209568A1 (fr) * | 2022-04-26 | 2023-11-02 | Novartis Ag | Anticorps multispécifiques ciblant il-13 et il-18 |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0154316B1 (fr) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Lymphokine chimiquement modifiée et son procédé de préparation |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
CA2006596C (fr) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | G-csf modifie chimiquement |
US5582996A (en) | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
DK0605522T3 (da) | 1991-09-23 | 2000-01-17 | Medical Res Council | Fremgangsmåde til fremstilling af humaniserede antistoffer |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
RU2128709C1 (ru) | 1992-01-23 | 1999-04-10 | Мерк Патент Гмбх | Способ получения димерного одноцепочечного слитого белка (варианты) |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
CA2118508A1 (fr) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Production par recombinaison genetique de domaines semblables aux immunoglobulines dans les cellules procaryotes |
CA2163345A1 (fr) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Anticorps |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US20030148463A1 (en) | 1997-04-14 | 2003-08-07 | Micromet Ag | Novel method for the production of anti-human antigen receptors and uses thereof |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
DE69942021D1 (de) | 1998-04-20 | 2010-04-01 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
DK2270149T3 (en) | 1999-04-09 | 2016-05-09 | Kyowa Hakko Kirin Co Ltd | PROCEDURE TO CONTROL THE ACTIVITY OF IMMUNOLOGICAL FUNCTIONAL MOLECULE. |
DK1522590T3 (da) | 2000-06-28 | 2009-12-21 | Glycofi Inc | Fremgangsmåde til fremstilling af modificerede glykoproteiner |
GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
US20030157108A1 (en) | 2001-10-25 | 2003-08-21 | Genentech, Inc. | Glycoprotein compositions |
CA2965865C (fr) | 2002-07-18 | 2021-10-19 | Merus N.V. | Production par recombinaison de melanges d'anticorps |
MX2007002856A (es) | 2004-09-02 | 2007-09-25 | Genentech Inc | Metodos para el uso de ligandos receptores de muerte y anticuerpos c20. |
JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
CN102861332A (zh) | 2005-10-26 | 2013-01-09 | 诺瓦提斯公司 | IL-1β化合物的新用途 |
KR20110079922A (ko) * | 2006-04-14 | 2011-07-11 | 노파르티스 아게 | 안과 장애 치료를 위한 il-1 항체의 용도 |
WO2008119353A1 (fr) | 2007-03-29 | 2008-10-09 | Genmab A/S | Anticorps bispécifiques et procédés de production de ceux-ci |
US8282922B2 (en) * | 2007-05-29 | 2012-10-09 | Novartis Ag | Method of treating an auto-inflammatory syndrome with a human IL-1β binding antibody |
BRPI0821311B1 (pt) | 2007-12-21 | 2018-09-18 | Novartis Ag | Ácido nucleico de vetor linearizado, método para produção de uma célula hospedeira de mamífero compreendendo o referido ácido, e método para produção de um polipetídeode interesse |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
SI2235064T1 (sl) | 2008-01-07 | 2016-04-29 | Amgen Inc. | Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov |
MX2010013236A (es) | 2008-06-03 | 2011-02-24 | Abbott Lab | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
MX2010014574A (es) | 2008-07-08 | 2011-04-27 | Abbott Lab | Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas. |
CA2734340C (fr) | 2008-08-28 | 2019-03-05 | Novartis Ag | Presentation sur la surface cellulaire d'isoformes de polypeptide par lecture de codon stop |
CA2753813C (fr) | 2009-02-27 | 2018-12-11 | Novartis Ag | Procede de selection de cellules hotes eucaryotes exprimant une proteine heterologue |
CA2753814C (fr) * | 2009-02-27 | 2018-07-31 | Novartis Ag | Systeme de vecteurs d'expression comprenant deux marqueurs de selection |
WO2011116387A1 (fr) * | 2010-03-19 | 2011-09-22 | Tetragenetics, Inc. | Production d'anticorps monoclonaux aglycosylés dans des ciliés |
CN103097417B (zh) | 2010-04-20 | 2019-04-09 | 根马布股份公司 | 含异二聚体抗体fc的蛋白及其制备方法 |
DK2606064T3 (en) | 2010-08-16 | 2015-04-20 | Novimmune Sa | Methods for generating multispecific and multivalent antibodies |
IN2013MN01438A (fr) | 2011-03-17 | 2015-06-12 | Univ Ramot | |
TWI622597B (zh) | 2011-03-28 | 2018-05-01 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
PL2771364T3 (pl) | 2011-10-27 | 2020-01-31 | Genmab A/S | Wytwarzanie heterodimerycznych białek |
SI2794905T1 (sl) | 2011-12-20 | 2020-08-31 | Medimmune, Llc | Modificirani polipeptidi za ogrodja bispecifičnega protitelesa |
JOP20200308A1 (ar) | 2012-09-07 | 2017-06-16 | Novartis Ag | جزيئات إرتباط il-18 |
EP2900764B1 (fr) | 2012-09-26 | 2017-07-19 | 3M Innovative Properties Company | Composition de revêtement, composition résistant aux salissures, articles résistant aux salissures et procédés pour les préparer |
WO2014110601A1 (fr) | 2013-01-14 | 2014-07-17 | Xencor, Inc. | Nouvelles protéines hétérodimères |
EP2961770A1 (fr) | 2013-02-26 | 2016-01-06 | Roche Glycart AG | Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t |
US9498543B2 (en) | 2013-03-15 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
BR112015022119A2 (pt) * | 2013-03-15 | 2017-08-29 | Abbvie Biotherapeutics Inc | Polipeptídeo, composto conjugado, composição farmacêutica, ácido nucleico, vetor, células hospedeiras procariótica e eucariótica, método de produção de um polipeptídeo, e, método de tratamento |
DK3587448T3 (da) | 2013-03-15 | 2021-08-09 | Xencor Inc | Heterodimere proteiner |
US11242551B2 (en) | 2013-12-20 | 2022-02-08 | Novartis Ag | Eukaryotic cells and methods for recombinantly expressing a product of interest |
EP3083676B1 (fr) | 2013-12-20 | 2019-08-28 | Novartis AG | Nouvelles cellules eucaryotes et procédés d'expression de manière recombinante d'un produit d'intérêt |
US20170002060A1 (en) * | 2014-01-08 | 2017-01-05 | Moderna Therapeutics, Inc. | Polynucleotides for the in vivo production of antibodies |
EP3160991A2 (fr) | 2014-06-25 | 2017-05-03 | Novartis AG | Compositions et procédés permettant d'obtenir des protéines à action prolongée |
GB201414823D0 (en) * | 2014-08-20 | 2014-10-01 | Argen X Bv | Multispecific antibodies |
US20160176969A1 (en) | 2014-11-26 | 2016-06-23 | Xencor, Inc. | Heterodimeric antibodies including binding to cd8 |
BR112017011092A2 (pt) | 2014-11-26 | 2017-12-26 | Xencor Inc | anticorpos heterodiméricos que ligam cd3 e antígenos de tumor |
EA037065B1 (ru) | 2014-11-26 | 2021-02-01 | Ксенкор, Инк. | Гетеродимерные антитела, связывающие cd3 и cd38 |
US10428155B2 (en) | 2014-12-22 | 2019-10-01 | Xencor, Inc. | Trispecific antibodies |
WO2016141378A1 (fr) | 2015-03-05 | 2016-09-09 | Think Surgical, Inc. | Procédés pour positionner et suivre un axe d'outil |
CN115536750A (zh) | 2015-05-08 | 2022-12-30 | 森科股份有限公司 | 结合cd3和肿瘤抗原的异二聚体抗体 |
WO2017011773A2 (fr) | 2015-07-15 | 2017-01-19 | Modernatx, Inc. | Acides nucléiques à codons optimisés codant des anticorps |
CN108283001B (zh) * | 2015-10-08 | 2022-08-19 | 酵活有限公司 | 包含κ和λ轻链的抗原结合多肽构建体及其用途 |
PE20190128A1 (es) * | 2016-04-13 | 2019-01-17 | Sanofi Sa | Proteinas de union triespecificas y/o trivalentes |
EP3515936A1 (fr) * | 2016-09-23 | 2019-07-31 | Elstar Therapeutics, Inc. | Molécules d'anticorps multispécifiques comprenant des chaînes légères lambda et kappa |
UY37758A (es) | 2017-06-12 | 2019-01-31 | Novartis Ag | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos |
-
2018
- 2018-06-05 UY UY0001037758A patent/UY37758A/es unknown
- 2018-06-06 AR ARP180101511 patent/AR112419A1/es unknown
- 2018-06-08 EP EP18742595.4A patent/EP3638692A1/fr active Pending
- 2018-06-08 CN CN201880036745.XA patent/CN110730788A/zh active Pending
- 2018-06-08 CA CA3061097A patent/CA3061097A1/fr active Pending
- 2018-06-08 CR CR20190558A patent/CR20190558A/es unknown
- 2018-06-08 SG SG10201913536TA patent/SG10201913536TA/en unknown
- 2018-06-08 PE PE2019002532A patent/PE20200384A1/es unknown
- 2018-06-08 KR KR1020197036605A patent/KR20200005746A/ko not_active IP Right Cessation
- 2018-06-08 JO JOP/2019/0283A patent/JOP20190283B1/ar active
- 2018-06-08 MX MX2019015021A patent/MX2019015021A/es unknown
- 2018-06-08 MA MA049394A patent/MA49394A/fr unknown
- 2018-06-08 WO PCT/IB2018/054140 patent/WO2018229612A1/fr active Application Filing
- 2018-06-08 JP JP2019567724A patent/JP7106234B2/ja active Active
- 2018-06-08 CU CU2019000100A patent/CU20190100A7/es unknown
- 2018-06-08 KR KR1020227042678A patent/KR102633368B1/ko active IP Right Grant
- 2018-06-08 EA EA201992670A patent/EA201992670A1/ru unknown
- 2018-06-08 AU AU2018284303A patent/AU2018284303B2/en active Active
- 2018-06-08 BR BR112019025904-0A patent/BR112019025904A2/pt unknown
- 2018-06-08 TW TW107119828A patent/TWI826377B/zh active
- 2018-06-11 US US16/005,088 patent/US20190002589A1/en not_active Abandoned
-
2019
- 2019-10-14 ZA ZA2019/06757A patent/ZA201906757B/en unknown
- 2019-12-04 IL IL271179A patent/IL271179A/en unknown
- 2019-12-10 EC ECSENADI201987580A patent/ECSP19087580A/es unknown
- 2019-12-10 CO CONC2019/0013838A patent/CO2019013838A2/es unknown
- 2019-12-10 CL CL2019003613A patent/CL2019003613A1/es unknown
-
2020
- 2020-04-09 US US16/844,999 patent/US11987644B2/en active Active
-
2021
- 2021-07-20 AU AU2021206810A patent/AU2021206810A1/en active Pending
-
2022
- 2022-05-11 JP JP2022078272A patent/JP2022116038A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49394A (fr) | Procédé de fabrication d'anticorps bispécifiques, anticorps bispécifiques et utilisation thérapeutique desdits anticorps | |
MA43658A (fr) | Anticorps anti-ror1, anticorps bispécifiques ror1 x cd3, et leurs procédés d'utilisation | |
MA50359A (fr) | Anticorps anti-cd38 et procédés d'utilisation | |
MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
MA46770A (fr) | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation | |
MA52742A (fr) | Anticorps bispécifiques dll3-cd3 | |
MA43018A (fr) | Anticorps anti-pd1 et procédés d'utilisation | |
MA50505A (fr) | Anticorps 2 + 1 bispécifiques (contorsbodies) | |
MA43197A (fr) | Constructions d'anticorps bispécifiques pour cdh3 et cd3 | |
MA43802A (fr) | Matières cellulosiques et procédés de fabrication et d'utilisation de celles-ci | |
MA50948A (fr) | Anticorps et procédés d'utilisation de ceux-ci | |
MA46529A (fr) | Anticorps anti-lag-3 et leurs procédés d'utilisation | |
MA42447A (fr) | Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation | |
MA42971A (fr) | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation | |
MA49726A (fr) | Formulation d'anticorps anti-cgrp | |
MA47499A (fr) | Anticorps anti-tau et leurs procédés d'utilisation | |
MA51552A (fr) | Anticorps anti-ox40 et procédés d'utilisation | |
MA50956A (fr) | Anticorps anti-cd137 et procédés d'utilisation correspondants | |
MA44054A (fr) | Plateforme d'anticorps bispécifique | |
MA42055A (fr) | Composés antimicrobiens et procédés de fabrication et d'utilisation de ceux-ci | |
MA43274A (fr) | Gilet portable pour l'application de thérapie pulmonaire et procédé associé | |
MA50169A (fr) | Procédé de production d'un électrocatalyseur | |
MA50831A (fr) | Organoïde d'organe et procédé de production associé | |
MA51417A (fr) | Constructions d'anticorps bispécifiques dirigés contre muc17 et cd3 | |
MA47362A (fr) | Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif |